SCHEMBL21995591

SCHEMBL21995591

COc1ccc(-c2cnc(Oc3cc(F)ccc3F)nc2)nn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD O00767 3/20 0.40
ALOX5AP P20292 2/20 0.38
FEN1 P39748 2/20 0.38
TP53 P04637 2/20 0.37
LMNA P02545 1/20 0.37
THRB P10828 1/20 0.37
TDO2 P48775 1/20 0.36
OXTR P30559 1/20 0.36
ERN1 O75460 1/20 0.36
SCN5A Q14524 3/20 0.35
SCN9A Q15858 3/20 0.35
ABCB11 O95342 1/20 0.35
CYP2C9 P11712 1/20 0.35
SCN1A P35498 1/20 0.35
SCN4A P35499 1/20 0.35
SCN2A Q99250 1/20 0.35
SCN3A Q9NY46 1/20 0.35
SCN8A Q9UQD0 1/20 0.35
SCN10A Q9Y5Y9 1/20 0.35
PDGFRB P09619 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31674501 1.00 SCD (0.40) SCDALOX5APFEN1TP53LMNA
SCHEMBL24155628 0.90 L3MBTL1 (0.43) SCDALOX5APFEN1TP53OXTR
SCHEMBL24155473 0.88 KMT2A (0.43) SCDALOX5APFEN1LMNAOXTR
SCHEMBL24156299 0.83 ALOX5AP (0.38) SCDALOX5APFEN1TP53LMNA
SCHEMBL24155494 0.82 MEN1 (0.41) SCDTDO2CYP2C9SCN4ACYP1A2
SCHEMBL24155485 0.81 SCD (0.37) SCDALOX5APFEN1TP53LMNA
SCHEMBL31674519 0.79 MEN1 (0.41) SCDPDGFRBPDGFRA
SCHEMBL24155464 0.79 MEN1 (0.41) SCDPDGFRBPDGFRA
SCHEMBL24155834 0.76 ALDH1A1 (0.41) ALOX5APFEN1LMNACYP1A2CYP3A4
SCHEMBL21995533 0.73 MEN1 (0.49) LMNAOXTRCYP2C9CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304558-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-10-02 US disclosed
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-12-30 US disclosed
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-12-30 US disclosed
EP-3887358-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY Otsuka Pharmaceutical Co., Ltd. (JP) 2021-10-06 EP disclosed
CN-113166076-A Heterocyclic compounds for the treatment of epilepsy 大塚制药株式会社 2021-07-23 CN disclosed
WO-2020111263-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY SLC6A11, SCN1A, SCN1B SCD 1187/4885ALOX5AP 1188/4885FEN1 4701/4885
US-20250304558-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY SLC6A11, SCN1A, KCNH1 SCD 1144/4885ALOX5AP 1196/4885FEN1 4745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.